Literature DB >> 1712244

Human carcinoma cells bind thrombospondin through a Mr 80,000/105,000 receptor.

R Yabkowitz1, V M Dixit.   

Abstract

The metastatic 11B squamous carcinoma cell line synthesizes and secretes high levels of the extracellular matrix glycoprotein thrombospondin (TSP) and displays aggressive invasiveness in a nude mouse model forming highly undifferentiated tumors. The importance of adhesion events involving extracellular matrix proteins and the tumorigenic cell surface in metastasis led us to investigate the nature of the 11B cell surface receptor for TSP. Using TSP affinity chromatography, a cell surface complex of molecular weight 80,000 and 105,000 was isolated that appears to function as a receptor for TSP. Binding was specific for the COOH-terminal Mr 140,000 fragment of TSP. TSP and the Mr 140,000 fragment competed for the binding of the 125I-labeled Mr 80,000/105,000 cell surface complex to TSP-coated microtiter wells in a dose-dependent manner with half-maximal inhibition observed at 16 and 40 micrograms/ml, respectively. In contrast, the NH2-terminal heparin-binding domain did not inhibit binding in a dose-dependent manner. Other extracellular matrix proteins, such as laminin, vitronectin, or type I collagen, were also unable to inhibit the binding of the 125I-labeled Mr 80,000/105,000 cell surface complex to TSP. The specificity of the Mr 80,000/105,000 receptor for the Mr 140,000 fragment of TSP was further confirmed through the use of monoclonal antibodies. Monoclonal antibody C6.7 specific for the distal COOH terminus of TSP, but not monoclonal antibody A2.5 specific for the heparin-binding domain, inhibited binding. Binding was observed to be strongly Ca2+ dependent, slightly Mg2+ dependent, and independent of Mn2+. Immunoprecipitation analyses demonstrated no apparent cross-reactivity between the Mr 80,000/105,000 TSP receptor and members of the beta 1 or beta 3 integrin receptor families. Additionally, V-8 protease mapping demonstrated that the Mr 80,000 and 105,000 polypeptide bands are not related to each other through proteolytic processing. This initial identification and characterization of a carcinoma cell TSP receptor should allow a more detailed examination of the role of TSP in metastatic adhesion and motility.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712244

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Thrombospondin as a mediator of cancer cell adhesion in metastasis.

Authors:  D A Walz
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

2.  Identification of cell adhesive active sites in the N-terminal domain of thrombospondin-1.

Authors:  P Clezardin; J Lawler; J Amiral; G Quentin; P Delmas
Journal:  Biochem J       Date:  1997-02-01       Impact factor: 3.857

3.  Interaction of platelet-derived growth factor with thrombospondin 1.

Authors:  P J Hogg; K A Hotchkiss; B M Jiménez; P Stathakis; C N Chesterman
Journal:  Biochem J       Date:  1997-09-15       Impact factor: 3.857

4.  Muskelin, a novel intracellular mediator of cell adhesive and cytoskeletal responses to thrombospondin-1.

Authors:  J C Adams; B Seed; J Lawler
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

5.  Binding and degradation of thrombospondin-1 mediated through heparan sulphate proteoglycans and low-density-lipoprotein receptor-related protein: localization of the functional activity to the trimeric N-terminal heparin-binding region of thrombospondin-1.

Authors:  H Chen; J Sottile; D K Strickland; D F Mosher
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

6.  Cell-type specific adhesive interactions of skeletal myoblasts with thrombospondin-1.

Authors:  J C Adams; J Lawler
Journal:  Mol Biol Cell       Date:  1994-04       Impact factor: 4.138

7.  Interaction of thrombospondin with platelet glycoproteins GPIa-IIa and GPIIb-IIIa.

Authors:  M A Kowalska; G P Tuszynski
Journal:  Biochem J       Date:  1993-11-01       Impact factor: 3.857

8.  CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells.

Authors:  D W Dawson; S F Pearce; R Zhong; R L Silverstein; W A Frazier; N P Bouck
Journal:  J Cell Biol       Date:  1997-08-11       Impact factor: 10.539

9.  Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain.

Authors:  G P Tuszynski; V L Rothman; M Papale; B K Hamilton; J Eyal
Journal:  J Cell Biol       Date:  1993-01       Impact factor: 10.539

10.  Thrombospondin modulates melanoma--platelet interactions and melanoma tumour cell growth in vivo.

Authors:  H Boukerche; O Berthier-Vergnes; E Tabone; M Bailly; J F Doré; J L McGregor
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.